Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEurocell Regulatory News (ECEL)

Share Price Information for Eurocell (ECEL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 134.00
Bid: 132.00
Ask: 136.00
Change: 0.00 (0.00%)
Spread: 4.00 (3.03%)
Open: 134.00
High: 134.00
Low: 134.00
Prev. Close: 134.00
ECEL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Year End Trading Update

23 Jan 2024 07:00

RNS Number : 5270A
Eurocell plc
23 January 2024
 

23 January 2024

EUROCELL PLC

("Eurocell" or the "Group")

 

Year End Trading Update - Profits In Line with Expectations; Strong Cash Flow

 

Eurocell plc, the market leading, vertically integrated UK manufacturer, recycler and distributor of innovative window, door and roofline PVC products, provides the following update for the year ended 31 December 2023.

 

Summary

The trends reported at our half year results in September continued for the remainder of 2023, with some further modest weakening in our key markets. Repair, maintenance and improvement (RMI) activity continues to be impacted by low consumer confidence and higher costs of living. The ongoing steep decline in new build activity reflects successive interest rate rises and falling house prices, with house builders reducing build rates in anticipation of falling sales.

 

Against the challenging market backdrop, we have delivered some resilience in the Group's sales performance for the year. We continue to focus on closely managing cost and cash flow and, as expected, have seen some easing of input cost pricing in H2.

 

Despite these challenges, we are pleased to confirm that we anticipate underlying profit before tax for the year ended 31 December 2023 to be in line with market expectations.

 

Trading Performance

Reported sales for the year ended 31 December 2023 were £365 million, down 4% on an exceptionally strong 2022 comparative period, with volume 6% lower. Comparisons by division were as follows:

 

Sales vs 2022

6 months to 30 June 2023

6 months to 31 Dec 2023

12 months to 31 Dec 2023

Total Group

-2%

-6%

-4%

Profiles Division

-1%

-8%

-4%

Building Plastics Division

-3%

-6%

-4%

 

Profiles - reduced RMI activity and a significantly weaker new build market, partially offset by the benefit of market share gains, resulted in sales volumes 7% below 2022. We have continued to acquire new fabricator accounts, supported by a reduction in UK capacity following the closure of the Duraflex extrusion business in September. In addition, some of our existing fabricators have benefited from an increase in volume following the administration of Safestyle in October.

 

Building Plastics - RMI volumes in the branch network were down 5% on 2022 and remain subdued, with increased competition for limited demand leading to ongoing pressure on margins. Sales include an increase in our made-to-order products, which extend living spaces, such as garden rooms.

As reported in September, we experienced persistent input cost inflation H1 2023, particularly for labour and electricity, which we offset with selling price increases where possible. In addition, recycling feedstock prices were significantly higher than the first half of 2022. However, as noted above, we have seen some easing of input cost pricing in H2.

 

As previously announced, in response to lower sales volumes, we took early and decisive action on costs, with restructuring programmes implemented in Q4 2022 and Q2 2023, securing annualised savings of £9 million, of which £7 million were realised in 2023. The related redundancy costs from the Q2 2023 programme, together with cloud computing costs incurred on strategic IT projects, will be reported as a non-underlying item of approximately £3.5 million in our 2023 financial statements.

 

We have also continued to focus on efficient inventory management to drive good cash flow performance. As a result, net cash on a pre-IFRS 16 basis was £0.4 million at 31 December 2023, compared to net debt of £14 million at 31 December 2022.

 

Review of Strategy

As reported in September, we have been reviewing our strategy, including the optimisation and expansion of the branch network, an enhanced customer proposition and simplified business structures. We expect to report the conclusions from our review at the time of our 2023 full year results announcement (see Notice of Results below).

 

Capital Allocation

The Board is focused on enhancing shareholder returns and recognises the importance of our ordinary dividend. We will also periodically consider supplementary distributions, whilst always seeking to maintain a strong financial position. Taking into account expected organic investment requirements and our successful cash flow management in 2023, which resulted in net cash of £0.4 million at the year end, we are now launching a £5 million share buyback programme, full details of which will be announced separately today.

 

Notice of Results

We expect to publish our results for the year ending 31 December 2023 on 20 March 2024.

 

This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) no. 596/2014 (including as it forms part of the laws of England and Wales by virtue of the European Union (Withdrawal) Act 2018) ('MAR').

 

 

Enquiries:

Eurocell plc

Darren Waters, Chief Executive Officer +44 (0) 1773 842 105

Michael Scott, Chief Financial Officer +44 (0) 1773 842 140

 

Teneo

Nick de Bunsen +44 (0) 7825 575 258

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTVLLFLZFLXBBV
Date   Source Headline
31st Jan 20237:00 amRNSHolding(s) in Company
26th Jan 20237:00 amRNSYear End Trading Update
6th Jan 20237:00 amRNSCEO Announces Intention to Retire in 2023
15th Nov 20227:04 amRNSHolding(s) in Company
14th Nov 20227:00 amRNSHolding(s) in Company
10th Nov 20224:00 pmRNSHolding(s) in Company
8th Nov 20223:59 pmRNSDirectorate Change
26th Oct 20227:00 amRNSHolding(s) in Company
7th Oct 20227:00 amRNSChanges to Board Committee memberships
5th Oct 20222:00 pmRNSHolding(s) in Company
3rd Oct 20227:00 amRNSTotal Voting Rights
5th Sep 20227:00 amRNSBlock listing Interim Review
5th Sep 20227:00 amRNSInvestor Presentation
1st Sep 20227:00 amRNSHalf-year Report
15th Aug 20223:00 pmRNSHolding(s) in Company
10th Aug 20223:45 pmRNSAppointment to the Audit & Risk Committee
13th Jul 20227:00 amRNSTrading Update
5th Jul 202212:25 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSTotal Voting Rights
22nd Jun 20227:00 amRNSDirector/PDMR Shareholding
21st Jun 202212:08 pmRNSDirectorate Change
25th May 20227:00 amRNSBlock Listing Application
16th May 20227:00 amRNSDirector/PDMR Shareholding
12th May 20224:00 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update and Board Update
14th Apr 20224:00 pmRNSDirector/PDMR Shareholding
14th Apr 20224:00 pmRNSDirector/PDMR Shareholding
8th Apr 20227:00 amRNSAnnual Financial Report
21st Mar 20227:00 amRNSInvestor Presentation
18th Mar 20227:00 amRNSPreliminary results for the year ended 31 Dec 2021
17th Mar 20227:00 amRNSNotice of Results and Audiocast
15th Mar 20223:05 pmRNSTransaction in Own Shares
9th Mar 20225:00 pmRNSBlock listing Interim Review
16th Feb 20227:00 amRNSAppointment of Joint Corporate Broker
21st Jan 20227:00 amRNSYear End Trading Update
4th Jan 20227:00 amRNSTotal Voting Rights
1st Dec 20217:00 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSTrading Update November 2021
1st Nov 20217:00 amRNSTotal Voting Rights
1st Oct 20217:00 amRNSTotal Voting Rights
7th Sep 20214:00 pmRNSInvestor Presentation
7th Sep 20211:38 pmRNSBlock listing Interim Review
3rd Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSTotal Voting Rights
2nd Aug 20217:00 amRNSTotal Voting Rights
20th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSTotal Voting Rights
1st Jun 20217:00 amRNSTotal Voting Rights
14th May 202111:18 amRNSResult of AGM
13th May 20217:00 amRNSAGM Trading Update – Strong First Four Months

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.